Oxford/AstraZeneca is the most widely given vaccine, administered in 170 of the 215 countries where campaigns have begun.
It is followed by Pfizer/BioNTech, which is being used in at least 97 countries; Moderna (at least 46); Sinopharm (45); Sputnik V (40); Johnson & Johnson (29).
Procurement and delivery of the vaccine is subject to Sputnik V receiving an emergency use listing from the World Health Organisation, a decision which the RDIF said is expected soon.
The vaccine will be exported to neighboring countries in South America, since Brazil has not yet approved the Russian shot for domestic use.
The factory's first batch of 100,000 doses were packed into boxes labeled in Spanish, although the countries receiving them have not been decided yet by the Russian Direct Investment Fund (RDIF), executives said.
"Ecuador joins a number of other nations of South America which have included Sputnik V in their coronavirus vaccine portfolios," Kirill Dmitriev, the head of RDIF, said in a statement.
If people aren't sure that the vaccine they are receiving is the same that was studied in trials, then "I can imagine that some people might have their reservations about getting that vaccine at all," said Rasmussen.
Sputnik V is the third drug to be approved by India after Oxford-AstraZeneca's Covishield and Covaxin, which was developed by Indian firm Bharat Biotech.
Moody's also echoed concerns raised by Barclays that a shortage of vaccines and India's population of nearly 1.4 billion could slow progress of the vaccine rollout.
